Human HDAC6 protein, GenBank Accession No. BC069243, full length with N-terminal GST-tag, MW= 159 kDa, expressed in baculovirus expression system.

Q9UBN7

histone deacetylase 6, HDAC-6, HDAC6 Protein

≥350 pmol/min/µg.

25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/ml BSA, 20 μM BPS HDAC substrate 3 (Catalog #50037), and HDAC6 (3.1 – 200 ng). Incubation condition: 30 min at 37ºC followed by developing for 15 min at room temperature.

40 mM Tris-HCl pH8.0, 110mM NaCl, 2.2 mM KCl,0.04% Tween20, 3mM DTT, and 20% glycerol

Protein was purified by affinity chromatography and gel filtration.

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Li S. et al., Neurology. 41(2), 112-6 (2010).
2. Strausberg, R.L. et al., Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002).

Application References:
1. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function (2017)
2. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration (2017)
3. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies (2017)
4. Molecular Simulation and Activity Studies of Oxametacin as an HDAC Inhibitor (2017)
5. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
6. Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity (2017)
7. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
8. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy (2017)
9. Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy (2017)
10. HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice (2017)
11. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015)
12. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
13. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
14. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors (2014)
15. Thermodynamics of ligand binding to histone deacetylase like amidohydrolase from Bordetella/Alcaligenes (2014)
16. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013)
17. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
18. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013)
19. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform (2013)
20. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013)
21. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors (2013)

Avoid freeze/thaw cycles.

Deacetylase

Recombinant Protein